MPO and Parkinson disease: We first searched for glial activators that could elevate MPO levels, and found that MPO levels were considerably increased by 1-methyl-4-phenylpyridinium (MPP+), a dopaminergic neurotoxin, which produces in vivo and in vitro cellular changes characteristic of PD.